Pharmacovigilance (QPPV) provision post-Brexit Archives

Filter by
Categories
Tags
Authors
Show all

All
Brexit Updates
Industry News
NCPP
Patient Information
Pharmacovigilance
Risk Management

All
Aimovig
Brexit updates
British Association for the Study of Headache
CGRP
chronic migraine
Deputy QPPV for Pharmacovigilance
EMA latest guidance
erenumab
EU MA
EU QPPV
EU QPPV for Pharmacovigilance
EU/EEA QPPV
European Marketing Authorisation Holders (MAH)
GCP inspections
Good Clinical Practice inspections
MAH Service
Marketing Authorisation Holders
MHRA latest guidance
MHRA post-transition period information
National Contact Person for Pharmacovigilance (NCPP)
NICE agrees to look again at Novartis’ Aimovig for migraine prevention
Novartis
Periodic Safety Update Reports
pharmacovigilance
Pharmacovigilance (QPPV)
Pharmacovigilance (QPPV) provision post-Brexit
Post-Authorisation Safety Studies-protocols and final study reports
PSMF (pharmacovigilance system master file)
Pure Drug Safety
QPPV (Qualified Person for Pharmacovigilance)
QPPVs based in the UK
remain compliant in the UK
Responsible Person for Eudravigilance in clinical trials
Risk Management Plans
severe migraine
the transition period for Pharmacovigilance and Regulatory
UK and non-UK Individual Case Safety Reports
UK QPPV

All
bone
Liselle Barnsley

7th February 2020

Pharmacovigilance (QPPV) provision post-Brexit

There has been and still is a huge amount of confusion regarding the requirements for establishing a UK QPPV following the UK’s exit from Europe on […]